Opus Genetics logo
Opus Genetics
IRD | NASDAQ
Chart Builder DCF Calculator
$4.04
+$0.06 (+1.51%)
At close: Nov 16, 2026, 4:00 PM ET
$4.10
+$0.06 (+1.49%)
After-hours: Nov 16, 2026, 7:30 PM ET

Opus Genetics Company Profile

Company profile explained

Company Profile

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.

Key Executives

Name Position
George Magrath Chief Executive Officer & Director
Chris Ernst Chief Technology Officer
Joseph K. Schachle Chief Operating Officer
Robert E. Gagnon Chief Financial Officer & Principal Accounting Officer
Amy Zaremba Rabourn Head of Financial Quality Assurance
Ashwath Jayagopal Chief Scientific & Development Officer
Benjamin R. Yerxa President & Director
Bernhard Hoffmann Senior Vice President of Corporate Development & Secretary
Bindu Manne Head of Market Development & Commercialization
Jenny Kobin Investor Relations Officer
Sally Tucker Chief Medical Officer & Senior Vice President of Clinical Development

Latest SEC Filings

Date Type Title
Oct 27, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 27, 2026 4 Filing
Oct 27, 2026 4 Filing
Oct 27, 2026 4 Filing
Oct 27, 2026 4 Filing
Oct 21, 2026 8-K Current Report
Oct 15, 2026 8-K Current Report
Oct 02, 2026 4 Filing
Sep 11, 2026 4 Filing
Sep 11, 2026 8-K Current Report
View All SEC Filings ➞
Opus Genetics
Opus Genetics logo
Country United States
IPO Date Jan 19, 2015
Industry Biotechnology
Sector Healthcare
Employees 28
CEO George Magrath

Contact Details

8 Davis Drive Durham, North Carolina 27713 United States

Stock Details

Ticker Symbol IRD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001228627
CUSIP Number 67577R102
ISIN Number US67577R1023
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.